Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica:
Abstract: Neuromyelitis optica (NMO) is an autoimmune demyelinating disorder of the central nervous system (CNS) with predilection for the optic nerves and spinal cord. Since its emergence in the medical literature in the late 1800's, the diagnostic criteria for NMO has slowly evolved from the simultaneous presentation of neurologic and ophthalmic signs to a relapsing or monophasic CNS disorder defined by clinical, neuroimaging, and laboratory criteria. Due to the identification of a specific autoantibody response against the astrocyte water channel aquaporin-4 (AQP4) in the vast majority of affected individuals, the clinical spectrum of NMO has greatly expanded necessitating the development of new international criteria for the diagnosis of NMO spectrum disorder (NMOSD). The routine application of new diagnostic criteria for NMOSD in clinical practice will be critical for future refinement and correlation with therapeutic outcomes.
http://ift.tt/2bO6KQN
Ιατρική : Τα αισθητικά συστήματα της όρασης,ακοής,αφής,γεύσης και όσφρησης.
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Delivered-To: alsfakia@gmail.com Received: by 2002:a4a:1484:0:0:0:0:0 with SMTP id 126csp3276540ood; Sun, 15 Nov 2020 22:05:16 -0...
-
ICHD-3 beta Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Di...
-
Abstract Owing to the functional versatility and potential applications in industry, interest in lipolytic enzymes tolerant to organic sol...
-
Abstract Objective Tooth agenesis is one of the most common craniofacial developmental anomalies. In hypodontia, one to five teeth are m...
-
Editor's Note In "Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse ...
-
AbstractBackground Recent evidence suggests that bioresorbable vascular scaffolds (BVS) are associated with an excess of thrombotic complic...
-
Abstract Background Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is the optimal treatment for EGFR-mutant advance...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου